TransCode Therapeutics, Inc.
RNAZ
$0.38
-$0.02-5.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.95M | 5.23M | 6.26M | 6.39M | 7.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.66M | 14.67M | 17.81M | 17.82M | 19.42M |
| Operating Income | -15.66M | -14.67M | -17.81M | -17.82M | -19.42M |
| Income Before Tax | -16.76M | -14.93M | -17.91M | -17.06M | -18.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.76 | -14.93 | -17.91 | -17.06 | -18.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.76M | -14.93M | -17.91M | -17.06M | -18.55M |
| EBIT | -15.66M | -14.67M | -17.81M | -17.82M | -19.42M |
| EBITDA | -15.57M | -14.55M | -17.68M | -17.69M | -19.29M |
| EPS Basic | -60.56 | -292.83 | -287.61 | -263.32 | -241.97 |
| Normalized Basic EPS | -37.85 | -183.02 | -179.76 | -164.57 | -151.23 |
| EPS Diluted | -60.56 | -292.83 | -287.61 | -263.32 | -241.97 |
| Normalized Diluted EPS | -37.85 | -183.02 | -179.76 | -164.57 | -151.23 |
| Average Basic Shares Outstanding | 1.42M | 831.40K | 386.40K | 172.70K | 16.90K |
| Average Diluted Shares Outstanding | 1.42M | 831.40K | 386.40K | 172.70K | 16.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |